B Biesma
Overview
Explore the profile of B Biesma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wachters F, Groen H, Biesma B, Schramel F, Postmus P, Stigt J, et al.
Br J Cancer
. 2004 Dec;
92(1):15-20.
PMID: 15597104
Response rate and toxicity of second-line therapy with docetaxel (75 mg m(-2)) or docetaxel, irinotecan, and lenogastrim (60 mg m(-2), 200 mg m(-2), and 150 microg m(-2) day(-1), respectively) were...
12.
OBrien M, Splinter T, Smit E, Biesma B, Krzakowski M, Tjan-Heijnen V, et al.
Eur J Cancer
. 2003 Jun;
39(10):1416-22.
PMID: 12826045
The aim of this study was to document the activity and toxicity of paclitaxel (Taxol)/carboplatin when used as induction chemotherapy in patients with stage IIIA N2 non-small cell lung cancer...
13.
Hoekstra C, Stroobants S, Hoekstra O, Vansteenkiste J, Biesma B, Schramel F, et al.
Lung Cancer
. 2003 Feb;
39(2):151-7.
PMID: 12581567
Combined modality treatment (CMT) for patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) is at present studied extensively. To select patients with truly stage IIIA-N2 disease, however, proves to...
14.
Tjan-Heijnen V, Caleo S, Postmus P, Ardizzoni A, Burghouts J, Buccholz E, et al.
Ann Oncol
. 2003 Feb;
14(2):248-57.
PMID: 12562652
Background: To determine whether the cost of prophylactic antibiotics during chemotherapy is offset by cost savings due to a decreased incidence of febrile leukopenia (FL). Patients And Methods: Small-cell lung...
15.
Tjan-Heijnen V, Postmus P, Ardizzoni A, Manegold C, Burghouts J, Van Meerbeeck J, et al.
Ann Oncol
. 2002 Jan;
12(10):1359-68.
PMID: 11762805
Background: CDE (cyclophosphamide, doxorubicin, etoposide) is one of the standard chemotherapy regimens in the treatment of small-cell lung cancer (SCLC), with myelosuppression as dose-limiting toxicity. In this trial the impact...
16.
Huisman C, Biesma B, Postmus P, Giaccone G, Schramel F, Smit E
Br J Cancer
. 2001 Nov;
85(10):1456-61.
PMID: 11720428
The purpose of this study is to determine whether it is feasible to administer high-dose epirubicin (135 mg m(-2)) combined with a fixed dose of cisplatin every 2 weeks with...
17.
Biesma B, Smit E, Postmus P
Lung Cancer
. 1999 Aug;
24(2):115-21.
PMID: 10444062
Background: Combination chemotherapy improves survival in patients with disseminated non-small cell lung cancer (NSCLC). Gemcitabine is active against NSCLC and etoposide has an additive effect in vitro. We describe a...
18.
Groen H, Fokkema E, Biesma B, Kwa B, Van Putten J, Postmus P, et al.
J Clin Oncol
. 1999 Mar;
17(3):927-32.
PMID: 10071286
Purpose: To evaluate the efficacy of paclitaxel and carboplatin (PC) in small-cell lung cancer (SCLC) patients resistant to cyclophosphamide, doxorubicin, and etoposide (CDE). Patients And Methods: We performed a phase...
19.
Tjan-Heijnen V, Biesma B, Festen J, Splinter T, Cox A, Wagener D, et al.
J Clin Oncol
. 1998 Aug;
16(8):2708-14.
PMID: 9704721
Purpose: To evaluate the impact of granulocyte colony-stimulating factor (G-CSF) priming on peripheral-blood cell counts during standard-dose chemotherapy. Patients And Methods: Twelve patients with relapsed small-cell lung carcinoma (SCLC) were...
20.
Smit E, Fokkema E, Biesma B, Groen H, Snoek W, Postmus P
Br J Cancer
. 1998 Feb;
77(2):347-51.
PMID: 9461009
The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients with...